Tekla Other Stockholder Equity vs Other Assets Analysis
HQL Stock | USD 13.32 0.17 1.29% |
Tekla Life financial indicator trend analysis is much more than just breaking down Tekla Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tekla Life Sciences is a good investment. Please check the relationship between Tekla Life Other Stockholder Equity and its Other Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
Other Stockholder Equity vs Other Assets
Other Stockholder Equity vs Other Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tekla Life Sciences Other Stockholder Equity account and Other Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Tekla Life's Other Stockholder Equity and Other Assets is -0.22. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Other Assets in the same time period over historical financial statements of Tekla Life Sciences, assuming nothing else is changed. The correlation between historical values of Tekla Life's Other Stockholder Equity and Other Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Tekla Life Sciences are associated (or correlated) with its Other Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Assets has no effect on the direction of Other Stockholder Equity i.e., Tekla Life's Other Stockholder Equity and Other Assets go up and down completely randomly.
Correlation Coefficient | -0.22 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Stockholder Equity
Other Assets
Most indicators from Tekla Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tekla Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. At this time, Tekla Life's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 18.05 this year, although the value of Selling General Administrative will most likely fall to about 692 K.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.4M | 1.2M | 1.3M | 861.3K | Cost Of Revenue | 5.5M | 5.2M | 6.0M | 3.9M |
Tekla Life fundamental ratios Correlations
Click cells to compare fundamentals
Tekla Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tekla Life fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 484.2M | 534.2M | 414.7M | 402.6M | 463.0M | 335.6M | |
Other Current Liab | (2.8M) | 567.3K | 10.7M | (5.1M) | (5.9M) | (5.6M) | |
Total Current Liabilities | 2.8M | 581.2K | 10.7M | 5.1M | 5.9M | 3.2M | |
Total Stockholder Equity | 483.6M | 523.4M | 397.9M | 401.9M | 462.2M | 332.0M | |
Net Debt | 5.0M | 1.3M | 10.6K | (477.0) | (548.55) | (575.98) | |
Cash | (5.0M) | 990.0 | 445.0 | 477.0 | 429.3 | 407.84 | |
Non Current Assets Total | 484.0M | 534.0M | 414.1M | 397.5M | 457.2M | 332.8M | |
Non Currrent Assets Other | (484.0M) | (534.0M) | (414.1M) | (397.5M) | (357.8M) | (375.7M) | |
Other Assets | 118.6K | 33.0K | 25.4K | 26.3K | 23.7K | 22.5K | |
Cash And Short Term Investments | 5.0M | 990.0 | 445.0 | 477.0 | 548.55 | 521.12 | |
Common Stock Shares Outstanding | 23.8M | 24.3M | 25.7M | 26.8M | 30.8M | 19.2M | |
Liabilities And Stockholders Equity | 484.2M | 534.2M | 414.7M | 402.6M | 463.0M | 335.6M | |
Total Liab | 595.2K | 10.7M | 16.8M | 667.0K | 767.0K | 728.7K | |
Total Current Assets | 73.9K | 144.7K | 623.9K | 5.0M | 5.8M | 6.1M | |
Common Stock | 238.8K | 246.7K | 256.8K | 267.9K | 308.1K | 292.7K | |
Net Receivables | 73.9K | 143.7K | 623.5K | 5.0M | 5.8M | 6.1M | |
Other Stockholder Equity | 356.3M | 372.5M | 388.1M | 403.1M | 463.6M | 486.8M | |
Net Tangible Assets | 383.7M | 483.6M | 523.4M | 397.9M | 457.6M | 449.7M | |
Retained Earnings | 127.0M | 150.7M | 9.5M | (1.5M) | (1.7M) | (1.6M) | |
Long Term Investments | 484.0M | 534.0M | 414.1M | 397.5M | 457.2M | 444.7M | |
Other Current Assets | (5.0M) | (17.3M) | (33.6M) | (20.3M) | (18.3M) | (17.3M) | |
Short Term Investments | 5.0M | 17.2M | 32.9M | 15.2M | 17.5M | 12.9M | |
Capital Stock | 238.8K | 246.7K | 256.8K | 267.9K | 241.1K | 229.1K | |
Non Current Liabilities Total | 569.2K | 9.4M | 5.1M | 667.0K | 600.3K | 570.3K |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tekla Life Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Tekla Stock analysis
When running Tekla Life's price analysis, check to measure Tekla Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Life is operating at the current time. Most of Tekla Life's value examination focuses on studying past and present price action to predict the probability of Tekla Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Life's price. Additionally, you may evaluate how the addition of Tekla Life to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Tekla Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Dividend Share 1.3 | Earnings Share 0.79 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.344 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.